Abstract | OBJECTIVES: METHODS: Medical records of 250 consecutive patients with a malignant disease who received gemcitabine-based therapy were reviewed. A multivariate analysis was done to determine factors associated with thromboembolism. RESULTS: A total of 220 eligible patients with a median age of 63 years (range 26-83) were identified. Of these 220 patients, 95% had advanced malignancy and 59% had received prior chemotherapy. A total of 69% of patients received a platinum combination. In all, 46% patients experienced thrombocytosis following chemotherapy, with a median platelet count of 632 × 10(9)/l (range 457-1,385). Twenty-three of the 220 patients experienced a vascular event within 6 weeks of treatment. Eleven patients with thrombocytosis experienced a vascular event compared with 10 patients without thrombocytosis (not significant). On multivariate analysis, leukocytosis (odds ratio 5.8, 95% confidence interval 2.1-15.8) and comorbid illnesses (odds ratio 4.1, 95% confidence interval 1.4-12.6) were correlated with thromboembolism. CONCLUSIONS:
|
Authors | S Ahmed, R K Shahid, H Bhatt, R Lee-Ying, J Lim |
Journal | Oncology
(Oncology)
Vol. 82
Issue 6
Pg. 327-32
( 2012)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 22627488
(Publication Type: Journal Article)
|
Copyright | Copyright © 2012 S. Karger AG, Basel. |
Chemical References |
- Organoplatinum Compounds
- Deoxycytidine
- Gemcitabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Female
- Humans
- Male
- Middle Aged
- Multivariate Analysis
- Organoplatinum Compounds
(administration & dosage, adverse effects)
- Platelet Count
(methods)
- Risk Factors
- Thrombocytosis
(chemically induced, pathology)
- Thromboembolism
(chemically induced, pathology)
- Gemcitabine
|